SERACH RESULTS FOR" Research "
Research & Development, Quality, Regulatory, Operations and product Commercialization. Mr. Machour served in a variety of positions of increased responsibility and scope and held senior and global leadership roles at Lonza, Becton Dickinson, Pfizer, J&J and Boehringer Ingelheim. Mr. Machour holds a Master’s degree from Concordia University in Physics and is a board member of George Mason University in Songdo. SENIOR VICE PRESIDENT / CFO Dongjoong Kim Dongjoong Kim is Senior Vice President and Managing Director in charge of the Business Resources Innovation Center which includes the Finance Team, Business Innovation Team and Global Employee Satisfaction Team. detail open Prior to joining Samsung Biologics in 2014, Mr. Kim held various corporate planning and managerial leadership positions for Samsung Electronics. Mr. Kim began his career with Samsung in 1988. Mr. Kim led the Corporate Management and Administration of Samsung Electronics from 2002 to 2014. SENIOR VICE PRESIDENT / CBO James Park James Park is Senior Vice President and Managing Director of the Global Business Development Center responsible for BD Operations Team, BD Innovation Team, BD Integration Team, Drug Product and small-scale CMO of Samsung Biologics. detail open Prior to joining Samsung Biologics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives. From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb. Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries. SENIOR VICE PRESIDENT Hoyeol (James) Yoon James Yoon is Senior Vice President and the Managing Director of the CC&C Center responsible for Communication, Procurement and Contract Development Services of Samsung Biologics. detail open Prior to joining Samsung Biologics in 2011, Mr. Yoon held various corporate planning and managerial leadership positions for Samsung Total Petrochemicals, a Joint Venture Company between Total of France and Samsung. Mr. Yoon began his career with Samsung in 1986. Mr. Yoon led the business development and financial restructuring of Samsung General Chemicals from 1997 to 2003. Mr. Yoon managed administration for the Joint Venture, including the negotiation of major license agreement for petrochemicals production plants. SENIOR VICE PRESIDENT / CIMO James Choi James Choi is Senior Vice President and Chief Information & Marketing Officer and head of Investor and Global Public Relations at Samsung Biologics. detail open Prior to joining Samsung Biologics in 2014, Mr. Choi held various technology and operations leadership positions at major global healthcare and informatics corporations. Mr. Choi began his career with Philips Healthcare in 1989 as Site Planning Manager and advanced through leadership positions in Customer Service eBusiness and Technology, Operations, and Information Systems for North America. Mr. Choi then transitioned to the Informatics and Security industry and was CIO for a major background investigations, in
Research and Development in the US and Europe. Mr. Rim has also held senior leadership roles with Astellas Pharmaceuticals in General Management, Sales & Marketing, Technical Operations, Customer Service, Business Development, and Strategic Planning. Mr. Rim has over 30 years’ experience in the biopharmaceutical industry and began his career as a management consultant with Booz, Allen & Hamilton consulting to pharmaceutical companies in the US and Europe. CEO Message Detail CEO Message For over a decade, Samsung Biologics has rapidly evolved into the world's largest and best-in-class CMO service provider, and now, we are continuously expanding our CDO and CRO business areas to make the next leap in biopharma. In this next decade, we will continue to build greater capabilities to meet new market demand as a top service provider in the biopharmaceutical industry while ensuring quality and stable supply of life-saving drugs. Since its launch, Samsung Biologics has not only expanded its manufacturing capacity but also established a solid track record of successful regulatory approvals and award-winning client satisfaction. In efforts to provide the highest level of customer-centric services, Samsung Biologics has implemented leading edge technologies and with great agility, demonstrated distinguished processes in terms of speed, price competitiveness, quality, and efficiency. We are facing a time of significant challenges and market dynamics. To respond proactively, we are making bold moves by adding Plant 4, with the largest and most flexible manufacturing scales, to our headquarters as well as carrying forward with global expansions with the CDO R&D Center. We expect synergies from collaborations between the new global locations and our manufacturing site in Songdo, a rising bio hub. With a steadfast vision and unrelenting drive to achieve better life for all, we embrace responsibility, expertise, and pride in our work, and will continue on our noble mission to enable improved accessibility of biomedicines and consequently the quality of life for people around the globe. We will challenge ourselves to improve in all facets of our business through innovation, dedication, and teamwork so that we can continue to add meaningful value to all of our clients, partners, and shareholders. Thank you for your continuous trust and support. John Rim President & CEO President & CEO, Samsung Biologics John Rim sign
Research and development relating to pharmaceutical products, subcontracting, advisory service;6.Education service and business service;7.Research service and investment business;8.Bioengineering and bio-pharmaceutical product research;9.Health and medical research;10.Joint research with domestic or international institutions;11.Technical research service for other domestic or international institutions;12.Plant design, purchasing agency, manufacture, construction, validation and supervision service;13.Real estate sale and purchase and leasing business;14.Transportation business;15.Parking lot business;16.Warehousing business;17.Businesses related to, necessary for, or incidental to any of the foregoing. Article 3 (Location of Head Office and Establishment of Branch, etc.) The Company shall have its head office in Incheon City and, if necessary, may establish branches, representative offices, business offices, sales offices, or local subsidiaries by a resolution of the Board of Directors (BOD) or of such a committee as authorized by the BOD. Article 4 (Method of Public Notices) The Company’s public notices shall be published in the Company’s website (http://samsungbiologics.com); provided, however, that in the event the public notices cannot be posted electronically due to computer system error or other unavoidable circumstances, the public notices shall be published in the JoongAng Ilbo, a daily newspaper of general circulation published in Seoul. Chapter 2.Shares Article 5 (Total Number of Shares Authorized to be Issued) The total number of shares that the Company is authorized to issue shall be Five Hundred Million (500,000,000) shares. Article 6 (Par Value per Share) The par value of each share to be issued by the Company shall be Two Thousand Five Hundred (2,500) won. Article 7 (Total Number of Shares to be Issued upon Incorporation) The total number of shares to be issued at the time of incorporation of the Company shall be One Million Five Hundred Thousand (1,500,000) shares. Article 8 (Classes of Shares and Share Certificates) ①The classes of shares to be issued by the Company shall be common shares and preferred shares, each of which shall be in registered form.②Preferred shares to be issued by the Company shall be preferred shares concerning dividends with non-voting rights, and the number of the preferred shares shall not be more than Fifty Million (50,000,000) shares.③Dividends on the preferred shares shall be first paid in cash at such dividend rate as determined by the BOD or such a committee as authorized by the BOD at the time of issuance based on the par value of the preferred shares.④In the event that the dividend rate of the common shares exceeds that of the preferred shares under Paragraph 3, any excess amount available for distribution after payment of dividends on the preferred shares and the common shares at the same ividend rate as that for the preferred shares shall be equally distributed to both common and preferred shareholders in proportion to their shareholding.⑤In the event that preferred dividends are not fully distributed on the preferred shares for any given fiscal year, any accumulated undistributed dividends shall be preferentially distributed first at the time of distribution of dividends in the immediately following fiscal year.⑥In case of rights issues, bonus issues or stock dividends, common shareholders shall be entitled to common shares, and preferred shareholders shall be entitled to preferred shares, in proportion to their respective shareholding; provided, however, that in case of rights issues, bonus issues or stock dividends, the Company may, if necessary, issue only one class of shares, where all the shareholders shall be entitled to such class of shares to be issued. Article 8-2(Electronic Registration of Rights to be Indicated on Shares and Stock Warrant Certificates) The Company shall electronically register rights to be indicated on shares and stock warrant c
Research- Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. Annual Operation Embedding BCMS is the ongoing cycle of activities of the business continuity management program, which builds organizational resilience, and is the professional practice that defines how to integrate business continuity awareness and practice into business as usual activities. Embedding BCMS Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Performing Risk and Threat Mitigation Measures Implementation - Implements the solutions agreed in the designed stage · Development of Tactical/Operational Business Continuity Strategy· Establishment of Business Continuity Plans & a response structure Validation - Confirms that the business continuity program meets the objectives set in the policy and the plans and procedures in place are effective. · Exercise Program: performing annual exercises with various types of scenario by each department as well as company-wide· Management Review to ensure it aligns with organizational objectives Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an inc
research on the harmful factors of musculoskeletal disorders and deliver a program for the prevention of musculoskeletal disorders to achieve a better working environment. Operation of Mental Health ClinicWe operate a variety of programs for mental health to prevent any mental health issues and mental health related accidents occurring for our valued employees. Industrial Hygiene Management Work Environment AssessmentWe continue to make the essential efforts to create healthy workplaces by measuring the exposure levels of harmful factors in the work environment in order to prevent any health problems and create a safe and pleasant working environment. Chemical Risk AssessmentWe assess the hazards of handling chemical substances and establish the relevant safety management measures to ensure that all our employees remain “chemically safe.” Hands-on Safety TrainingWe run hands-on training programs to enhance the safety and emergency response capabilities of all our employees.
research. "We are very excited to participate in the first face-to-face BIO International Convention in three years since the pandemic and to introduce our latest and innovative CDMO capabilities to clients,” said John Rim, CEO and President of Samsung Biologics. "We are continuously evolving to offer services for CDO, mRNA, and multi-modal products to further secure the success drivers for sustainable growth. We are also at the forefront in the biopharma industry to address critical issues like climate change as we aim to provide sustainable and enduring value for people worldwide and contribute to making the world a healthier place for all.” Driven. For a Sustainable Life.Samsung Biologics presented its commitment to sustainability at the ESG section of the booth and showcased the company’s promise to become a “Green CDMO.” The company launched its new sustainability branding video, “Driven. For Sustainable Life.”, to mark the promise of building a healthier and sustainable future for all. “With our aims to become a sustainable partner and a ‘Green CDMO’, we are actively investing in environment-conscious practices and technologies to mitigate the risks of climate change in the greater areas we impact,” said James Choi, EVP and Chief Information & Marketing Officer. “We are also working collaboratively on many global initiatives to help drive the net zero transition across the industry.” Last year, Samsung Biologics joined together with leaders from global biopharma companies and public sector organizations including the WHO and Unicef, as part of the Sustainable Markets Initiative (SMI), convened by His Royal Highness The Prince of Wales, to accelerate the delivery of net zero and establish sustainable healthcare to improve individual, societal, and planetary health. “Samsung Biologics is also working at an industry-level to drive successful decarbonization,” Choi added. "We joined the Frontier 1.5D project to develop a climate risk management model, which affirms our commitment to shaping climate-resilient practices and policies across all value chains in the pharmaceutical and healthcare sectors.” Addressing Key Insights into the Next BlockbusterIn addition to exhibition booths and networking receptions, over 100+ panel sessions covered various industry topics, such as next-generation biotherapeutics, mRNA, public policy, patient advocacy, and more. Pierre Catignol, Executive Vice President and Head of the Manufacturing Center, participated in a panel session to address key insights into mRNA and give guidance on what to look for in a CDMO partner. During the session, Catignol introduced the unique capabilities of Samsung Biologics and how it offers fully integrated mRNA manufacturing services all at a single site in Songdo. Limitless Together to Bring New Opportunities “BIO International is a place where bio-industry professionals and experts can come together to explore ways to cooperate and create new opportunities. This year’s theme of ‘Limitless Together’ is to show the cross-boundary collaboration of bio officials and the unlimited challenges in unknown areas,” said Adela Wilson from BIO. “Samsung Biologics’ performance was remarkable, both with its creative booth design and outstanding service competitiveness.” Samsung Biologics is at the forefront of building a sustainable future for all. By leveraging its world’s largest manufacturing capacity and continuous innovation, the company will strive to make innovative biologics accessible to all and create a healthier future. Driven. For Life. Related ContentsBIO Insight The Power of One I Samsung Biologics’ mRNA CapabilitiesLife @ Samsung Biologics Driven. For Climate Action
research that I helped compile during my internship will influence our client's decision and ultimately be able to manufacture a drug that helps save people's lives. Yoon-Bin Bae | Analytics Group, CDO R&D Intern(Major in Chemical – Biological Engineering, Massachusetts Institute of Technology) My internship has been a pleasant refresher, but also ‘CHALLENGING’ at the same time. It pushed me to be a better and smarter worker, and I hope my efforts can transform possibilities into actions for our biopharmaceutical clients and patients. Hyun-Su Kim | DSP Group, Manufacturing Technology Intern(Major in Biochemical Engineering, University of Illinois at Urbana-Champaign) If I could sum up in one word my internship at Samsung Biologics, it would be ‘RESPONSIBILITY’. I felt a sense of duty to the work I did and it inspired me to want to continue exploring the difference in cell culture growth between small scale run versus large scale. Sung-Dae Kim | USP Group, Manufacturing Technology Intern(Major in Biochemical Engineering, University of Illinois at Urbana-Champaign) My goal is to become a leading contributor and innovator in the pharmaceutical industry to bring a positive influence to the world. I would say my internship was very ‘ADVENTUROUS’ Every single day at Samsung Biologics fueled my passion for exploration and creating bold ideas. Ye-Jin Kim | Site GMP Compliance, Quality Operations Intern(Major in Chemistry, University of Illinois at Urbana-Champaign) Together, we can make a better life and better future.Driven. For Life. Related ContentsCareers Roles in Samsung BiologicsYouTube Samsung Biologics Internship: Most Memorable Experiences YouTube A Day in The Life of a Samsung Biologics Intern
research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing.” Samsung Biologics demonstrated strong operational performance and business agility in 2021 with all Plants 1, 2, and 3 in stable operations. Plant 4 will commence partial operations in Q4 this year with full completion expected mid-next year, and the company will also begin construction of Plant 5 within 2022 where it will offer multi-modal product services in addition to the mRNA vaccine drug substance (DS) manufacturing suite expected to be ready for cGMP operations within the earlier part of this year. About the CMO Leadership AwardsNow in its 11th year, Outsourced Pharma and Life Science Leader’s CMO Leadership Awards provide readers with accurate and reliable customer feedback to assist them in choosing a reputable partner for their development and manufacturing needs. For the 2022 CMO Leadership Awards, Industry Standard Research (ISR) determined the award recipients through their evaluation of more than 86 contract manufacturers. These CMOs were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. For more information about the awards, visit the awards website.
파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.
뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in EffectFebruary 25, 2020
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drugmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Naming Biopharmaceutical Products 1 Monoclonal Antibody Drugsmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Agreement for Novel Targetmore
-Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Targetmore